Disclaimer: This article is for research and educational purposes only. Ipamorelin and CJC-1295 are research compounds not approved by the FDA, Health Canada, or any regulatory agency for human therapeutic use. Nothing in this article constitutes medical advice. These compounds are intended strictly for licensed research applications.
Among growth hormone-related research peptides, few pairings generate as much sustained search interest as ipamorelin and CJC-1295. Both compounds target the growth hormone axis — but through distinct mechanisms, different receptor classes, and with meaningfully different evidence profiles.
In 2026, both remain actively studied and widely sourced as research reagents in Canada and internationally. Yet much of the available content conflates the two, misrepresents their mechanistic relationship, or — most commonly — skips straight to protocol recommendations without establishing what the research actually shows.
This post provides a rigorous, evidence-anchored comparison: mechanism, research findings, regulatory status, and the key questions researchers working with either compound need to understand.
Understanding the Growth Hormone Axis: Why These Two Compounds Work Differently
Growth hormone (GH) secretion from the anterior pituitary is regulated by two primary hypothalamic signals:
- Growth Hormone-Releasing Hormone (GHRH) — stimulates GH release
- Somatostatin — inhibits GH release
A third pathway — the ghrelin receptor (GHS-R1a), activated by growth hormone secretagogues (GHSs) — also potently stimulates GH secretion and operates partially independently of the GHRH/somatostatin axis.
Ipamorelin and CJC-1295 engage these pathways differently:
| Compound | Receptor Target | Class | Primary Action |
|—|—|—|—|
| Ipamorelin | GHS-R1a (ghrelin receptor) | GHRP (Growth Hormone-Releasing Peptide) | Stimulates GH pulses via ghrelin pathway |
| CJC-1295 | GHRH receptor (GHRH-R) | GHRH analogue | Amplifies GHRH signalling; extends GH pulse amplitude |
This distinction matters: the two compounds act on different receptor systems. Their co-administration in research models targets both pathways simultaneously — which is the mechanistic rationale behind their frequent use in tandem.
Ipamorelin: What It Is and What the Evidence Shows
Compound Profile
Ipamorelin is a synthetic pentapeptide (5 amino acids) developed in the late 1990s as a selective growth hormone secretagogue. Its defining characteristic in preclinical research is selectivity — it stimulates GH release without meaningfully elevating cortisol, prolactin, or ACTH at studied doses.
This selectivity set it apart from earlier GHRPs (GHRP-2, GHRP-6), which produced significant cortisol and prolactin responses in animal models.
Evidence Summary
| Research Area | Evidence Level | Key Findings |
|—|—|—|
| GH pulse stimulation | Strong (animal + limited human) | Robust GH secretion in rodent models; Phase 1 data in humans confirms GH elevation |
| Selectivity vs. other GHRPs | Moderate (animal) | Lower cortisol/ACTH co-stimulation than GHRP-2 or GHRP-6 in preclinical models |
| Bone mineral density | Low–Moderate (animal) | Increased bone density in ovariectomized rat models |
| Body composition | Low (animal) | Some lean mass effects in rodent models; human data absent |
| GI motility | Low–Moderate (animal + early human) | Ipamorelin showed prokinetic effects in post-operative ileus models; one Phase 2a trial in humans was conducted by Helsinn |
| Long-term safety (human) | Absent | No completed Phase 3 trials; full human safety profile unknown |
Notable: Helsinn Therapeutics advanced ipamorelin as far as Phase 2a for post-operative ileus (gastrointestinal motility indication) — one of the few cases where a research peptide reached an actual clinical trial stage. The trial was not completed for the full indication. This human data, though limited, provides more clinical context than most research peptides have.
CJC-1295: The GHRH Analogue (DAC vs. No DAC)
Compound Profile
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone. The critical specification for researchers: there are two distinct versions of CJC-1295, and conflating them is one of the most common errors in this space.
- CJC-1295 with DAC (Drug Affinity Complex): Contains a lysine residue modified to bind albumin in plasma. This dramatically extends the compound’s half-life from minutes to approximately 6–8 days. This version is sometimes called “CJC-1295 with DAC” or referred to as DAC-GRF.
- CJC-1295 without DAC (also called “Modified GRF 1-29” or “Mod GRF 1-29”): A shorter-acting GHRH analogue without the albumin-binding modification. Half-life measured in minutes, producing a pulse-like GH response.
| Version | Half-Life | GH Release Pattern | Notes |
|—|—|—|—|
| CJC-1295 with DAC | ~6–8 days | Sustained elevation (“GH bleed”) | Long-acting; some researchers prefer pulsatile GH profiles |
| CJC-1295 without DAC (Mod GRF 1-29) | ~30 minutes | Pulsatile, time-limited | More closely mimics natural GHRH pulsatility |
The distinction is pharmacologically significant. Sustained GH elevation (from DAC versions) and pulsatile GH release (from non-DAC versions) have different physiological implications in animal models.
Evidence Summary
| Research Area | Evidence Level | Key Findings |
|—|—|—|
| GH and IGF-1 elevation | Moderate (animal + limited human) | Robust GH/IGF-1 increases in rodent models; small human Phase 1/2 studies by ConjuChem confirmed GH elevation with CJC-1295 DAC |
| Sustained vs. pulsatile GH | Theoretical | No head-to-head studies comparing DAC vs. no DAC outcomes |
| Body composition | Low (animal) | Some lean mass effects in rodents at pharmacological doses |
| Anti-aging / GH restoration | Speculative | Common community claim; not supported by human trial data |
| Human Phase 3 data | Absent | No completed Phase 3 trials for any indication |
Ipamorelin vs. CJC-1295: Direct Comparison
| Feature | Ipamorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
|—|—|—|—|
| Receptor target | GHS-R1a (ghrelin) | GHRH receptor | GHRH receptor |
| Half-life | ~2 hours | ~30 minutes | ~6–8 days |
| GH release pattern | Pulsatile | Pulsatile | Sustained |
| Selectivity | High (low cortisol/prolactin) | Moderate | Moderate |
| Strongest evidence area | GI motility (Phase 2a); GH selectivity | GH/IGF-1 elevation (preclinical + Phase 1) | GH/IGF-1 elevation (Phase 1 only) |
| Human clinical trial data | Phase 2a (GI indication; Helsinn) | Phase 1/2 (ConjuChem; GH elevation) | Phase 1/2 (ConjuChem; GH elevation) |
| Regulatory approval | None | None | None |
| Canadian regulatory status | Research reagent only | Research reagent only | Research reagent only |
The “Stack” Rationale
The mechanistic case for combining ipamorelin (GHS-R1a) with CJC-1295 without DAC (GHRH-R) is that the two pathways are synergistic: GHRH receptor stimulation amplifies GH pulse amplitude, while ghrelin pathway activation increases GH pulse frequency. Animal studies using GHRH analogues combined with GHSs have generally confirmed additive or synergistic GH responses.
However: as with most research peptide “stacks,” no published studies have specifically examined ipamorelin + CJC-1295 in combination. The synergy rationale is mechanistically sound, but the combined-compound evidence base does not exist.
Regulatory Status in 2026: Canada and the U.S.
Canada
Neither ipamorelin nor CJC-1295 (in either form) holds a Drug Identification Number (DIN) or Natural Product Number (NPN) from Health Canada. Both are available as research reagents for licensed laboratory research.
Canadian researchers sourcing these compounds should verify:
- HPLC purity data (≥98% is the accepted standard for research-grade peptides)
- Mass spectrometry confirmation of amino acid sequence
- Third-party Certificate of Analysis (CoA)
- Supplier compliance with applicable Canadian import and reagent regulations
United States
Neither compound is FDA-approved for any therapeutic indication. The FDA’s updated 503A bulk substances framework does not include ipamorelin or CJC-1295 in any compounding-approved category. Both are research-use-only in the U.S. context.
Frequently Asked Questions
Q: What is the main difference between ipamorelin and CJC-1295?
Ipamorelin is a growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a), producing pulsatile GH release. CJC-1295 is a GHRH analogue that acts on GHRH receptors — the DAC version sustains elevated GH for days, while the non-DAC version (Mod GRF 1-29) produces a shorter pulse. They target different receptor systems and can be viewed as mechanistically complementary.
Q: What does “CJC-1295 with DAC” vs. “without DAC” actually mean?
DAC stands for Drug Affinity Complex — a chemical modification that allows the peptide to bind to albumin in plasma, dramatically extending its half-life from ~30 minutes to ~6–8 days. The two versions have fundamentally different pharmacokinetic profiles and GH release patterns. Researchers should specify which version they are working with in all documentation.
Q: Has ipamorelin been tested in humans?
Yes, to a limited degree. Helsinn Therapeutics conducted at least one Phase 2a clinical trial of ipamorelin for post-operative gastrointestinal ileus — making it one of the relatively few research peptides with some human trial data. The trial addressed a GI motility indication, not a body composition or GH-restoration indication. Full Phase 3 trials were not completed.
Q: Are ipamorelin or CJC-1295 legal to research in Canada?
Both compounds can be sourced as research reagents from licensed Canadian suppliers for laboratory research applications. Neither has a Health Canada DIN or NPN and neither is approved for human therapeutic use. Researchers should confirm applicable institutional and regulatory requirements.
Q: Can these compounds be combined in research?
In animal model research, GHRH analogues and GHSs are sometimes studied in combination because they target distinct receptor pathways with potential additive or synergistic effects on GH secretion. No published studies have specifically examined ipamorelin + CJC-1295 in combination. All combined-compound rationales remain theoretical extrapolations.
Conclusion
Ipamorelin and CJC-1295 occupy different positions on the growth hormone axis — one a ghrelin-pathway secretagogue, the other a GHRH receptor analogue — which is precisely why they’re often discussed together in research contexts. The mechanistic rationale for studying them in tandem is sound, even if combined-compound data does not yet exist.
For researchers approaching either compound, the key distinctions to keep straight are: ipamorelin’s selectivity profile versus earlier GHRPs, and the critical pharmacokinetic difference between CJC-1295 with DAC and without DAC. Misspecifying the version is among the most common sourcing errors in this category.
WebberScience supplies research-grade ipamorelin and CJC-1295 (both DAC and no-DAC formulations) with full HPLC purity data, mass spectrometry sequence confirmation, and Certificate of Analysis documentation for Canadian research institutions. For sourcing details or questions about your research program, contact our team or browse our research catalog.
This article is for educational and informational purposes only. Ipamorelin and CJC-1295 are research compounds not approved for human use by the FDA, Health Canada, or any regulatory body. This content does not constitute medical advice.